» Articles » PMID: 36854893

Diabetes Mellitus is Associated with 90-day Mortality in Old Critically Ill COVID-19 Patients: a Multicenter Prospective Observational Cohort Study

Abstract

Background: Several studies have found an association between diabetes mellitus, disease severity and outcome in COVID-19 patients. Old critically ill patients are particularly at risk. This study aimed to investigate the impact of diabetes mellitus on 90-day mortality in a high-risk cohort of critically ill patients over 70 years of age.

Methods: This multicentre international prospective cohort study was performed in 151 ICUs across 26 countries. We included patients ≥ 70 years of age with a confirmed SARS-CoV-2 infection admitted to the intensive care unit from 19th March 2020 through 15th July 2021. Patients were categorized into two groups according to the presence of diabetes mellitus. Primary outcome was 90-day mortality. Kaplan-Meier overall survival curves until day 90 were analysed and compared using the log-rank test. Mixed-effect Weibull regression models were computed to investigate the influence of diabetes mellitus on 90-day mortality.

Results: This study included 3420 patients with a median age of 76 years were included. Among these, 37.3% (n = 1277) had a history of diabetes mellitus. Patients with diabetes showed higher rates of frailty (32% vs. 18%) and several comorbidities including chronic heart failure (20% vs. 11%), hypertension (79% vs. 59%) and chronic kidney disease (25% vs. 11%), but not of pulmonary comorbidities (22% vs. 22%). The 90-day mortality was significantly higher in patients with diabetes than those without diabetes (64% vs. 56%, p < 0.001). The association of diabetes and 90-day mortality remained significant (HR 1.18 [1.06-1.31], p = 0.003) after adjustment for age, sex, SOFA-score and other comorbidities in a Weibull regression analysis.

Conclusion: Diabetes mellitus was a relevant risk factor for 90-day mortality in old critically ill patients with COVID-19.

Study Registration: NCT04321265, registered March 19th, 2020.

Citing Articles

Impact of Diabetes Mellitus On In-Hospital Mortality of COVID-19 Patients in Japan Since COVID-19 Became a Common Infectious Disease.

Fujita Y, Hatazaki M, Fujimi S Cureus. 2024; 16(8):e66373.

PMID: 39246912 PMC: 11378744. DOI: 10.7759/cureus.66373.


Clinical Manifestations and Outcomes of Older Patients with COVID-19: A Comprehensive Review.

Lee J, Kang D, Kim S, Kim D, Lee S Tuberc Respir Dis (Seoul). 2024; 87(2):145-154.

PMID: 38368903 PMC: 10990616. DOI: 10.4046/trd.2023.0157.


Diabetes Mellitus and Its Association with Adverse In-Hospital Outcomes in Patients with COVID-19-A Nationwide Study.

Schmitt V, Hobohm L, Sagoschen I, Sivanathan V, Hahad O, Espinola-Klein C Viruses. 2023; 15(8).

PMID: 37631970 PMC: 10457863. DOI: 10.3390/v15081627.

References
1.
Wu Z, McGoogan J . Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020; 323(13):1239-1242. DOI: 10.1001/jama.2020.2648. View

2.
Taylor E, Marson E, Elhadi M, Macleod K, Yu Y, Davids R . Factors associated with mortality in patients with COVID-19 admitted to intensive care: a systematic review and meta-analysis. Anaesthesia. 2021; 76(9):1224-1232. PMC: 8444810. DOI: 10.1111/anae.15532. View

3.
Walsh E, Frenck Jr R, Falsey A, Kitchin N, Absalon J, Gurtman A . Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. N Engl J Med. 2020; 383(25):2439-2450. PMC: 7583697. DOI: 10.1056/NEJMoa2027906. View

4.
Voysey M, Clemens S, Madhi S, Weckx L, Folegatti P, Aley P . Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2020; 397(10269):99-111. PMC: 7723445. DOI: 10.1016/S0140-6736(20)32661-1. View

5.
Gottlieb R, Vaca C, Paredes R, Mera J, Webb B, Perez G . Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients. N Engl J Med. 2021; 386(4):305-315. PMC: 8757570. DOI: 10.1056/NEJMoa2116846. View